Developing drugs to modulate the production of TNFα, such as NF-κB, P38 MAPK, and TNF receptor antagonist inhibitors, may be potential candidates for the treatment of cognitive impairment, AD, and other neurodegenerative diseases. This evidence concerns the gene NFKB1 and Alzheimer disease.